Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$150.30 USD

150.30
680,430

+0.34 (0.23%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

IDEXX (IDXX) Enhances Fecal Dx Antigen Testing Platform

by Zacks Equity Research

IDEXX's (IDXX) Fecal Dx antigen testing detects the most prevalent and clinically relevant intestinal parasites in dogs and cats.

Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

Veeva Systems (VEEV) Offerings Adopted by SK Life Science

by Zacks Equity Research

Veeva Systems' (VEEV) Vault Validation Management is expected to aid SK Life Science to accelerate validation processes for increased inspection readiness.

Best Growth Stocks to Buy for January 15th

by Zacks Equity Research

DVA, AZZ and ELF made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 15, 2024.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: DaVita, Block, Home Depot in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics

by Zacks Equity Research

Quest Diagnostics' (DGX) new partnership is likely to leverage its oncology expertise and national scale.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors remain optimistic about Align Technology (ALGN) due to the progress in the Invisalign portfolio and highly favorable solvency.

Shaun Pruitt headshot

Don't Overlook These Top Value Stocks in January It's Time to Buy

by Shaun Pruitt

With "A" Zacks Style Scores grades for Value here are three top-rated stocks with fundamental valuations that shouldn't be overlooked at the moment.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.

Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand

by Zacks Equity Research

Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.

Masimo (MASI) Posts Preliminary Q4 Results, Issues FY24 View

by Zacks Equity Research

Masimo's (MASI) fourth-quarter 2023 results are likely to reflect the impacts of the robust adoption of hearable products.

QIAGEN (QGEN) Wins FDA Clearance for NeuMoDx CT/NG Assay

by Zacks Equity Research

QIAGEN (QGEN) receives FDA clearance for the NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 versions of the integrated PCR-based clinical molecular testing system.

Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand

by Zacks Equity Research

Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.

Intuitive Surgical (ISRG) Preliminary Q4 Revenues Improve Y/Y

by Zacks Equity Research

Intuitive Surgical's (ISRG) fourth-quarter revenues reflect a strong demand in procedure volume as China recovers following the resurgence of COVID-19 in early 2023.

LabCorp (LH) to Expand Clinical Trails Access With New Pact

by Zacks Equity Research

LabCorp (LH) and Hawthorne Effect hope to enhance decentralized clinical trials by merging existing services and developing fresh, unique service offers.

Integer Holdings (ITGR) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.

The Zacks Analyst Blog Highlights DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics

by Zacks Equity Research

DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics are part of the Zacks top Analyst Blog.

Medtronic's (MDT) Percept RC DBS System Secures FDA Approval

by Zacks Equity Research

Medtronic's (MDT) latest innovation joins the Percept family, the first and only DBS system with sensing, directionality and advanced programming.

Acadia Healthcare (ACHC) Inks JV to Better Serve Texas Residents

by Zacks Equity Research

Acadia Healthcare (ACHC) enters into a JV with Ascension Seton to expand the availability of inpatient behavioral beds across Austin and thereby, establish a solid footprint in the region.

Neogen's (NEOG) Q2 Earnings Miss Estimates, 2024 View Down

by Zacks Equity Research

Neogen's (NEOG) Q2 revenues decline year over year due to lower Animal Safety business.

Veradigm (MDRX) & MedAllies Partner for Better Care Decisions

by Zacks Equity Research

Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.

Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales

by Zacks Equity Research

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

Is Quest Diagnostics (DGX) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.